Erin Cook
Education
Sc.D., cancer epidemiology, Harvard T.H. Chan School of Public Health; M.P.H., health policy, Dartmouth College; B.A., French, Washington University in St. Louis
Summary of Experience
Dr. Cook is an experienced epidemiology and health outcomes researcher, with a particular focus on real-world data assessment. She has conducted multiple studies in a variety of therapeutic areas, including dementia, oncology, cardiovascular disease, nutrition, and chronic inflammatory disorders. Dr. Cook’s research has covered a wide range of methodologies, including health economics (e.g., policy analyses, cost-effectiveness analysis, budget impact models); systematic literature review and indirect comparisons; trial analysis; patient surveys; and retrospective database analyses (e.g., claims and electronic medical record research). She has presented her work at numerous conferences and been published in peer-reviewed scientific medical journals.
- 
                                                        Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE StudyAdvances in Therapy, 2024 
 2024Yarur A, Mantzaris GJ, Wang S, Adsul S, Kamble P, Cook E, Sajeev G, Guerin A, Bressler B 
- 
                                                        Hyperkalemia and Risk of Chronic Kidney Disease Progression: A Propensity Score Matched AnalysisKidney360, 2024 
 2024Agiro A, Cook E, Mu F, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desa P, Chertow GM 
- 
                                                        Economic burden of recurrent hyperkalemia in patients with chronic kidney diseaseJournal of Managed Care & Specialty Pharmacy, 2024 
 2024Bakris G, Agiro A, Greatsinger A, Mu F, Cook EE, Sundar M, Louden E, Colman E, Desai P 
- 
                                                        Real-World Effectiveness of Benralizumab Among Patients with Asthma and Concomitant Chronic Obstructive Pulmonary DiseaseInternational Journal of Chronic Obstructive Pulmonary Disease, 2024 
 2024Carstens DD, Maselli DJ, Cook EE, Mu F, Chen J, Yang D, DeMartino JK , Chung Y 
- 
                                                        Association of Serum Calcium and Phosphate with Incident Cardiovascular Disease in Patients with HypoparathyroidismAmerican Journal of Cardiology, 2023 
 2023Kaul S, Ayodele O, Chen K, Cook EE, Swallow E, Rejnmark L, Gosmanova EO 
- 
                                                        Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-Jslm [FMBL]) for Preventing Recurrent Clostridioides Difficile Infection in the USAdvances in Therapy, 2023 
 2023Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, Bochan M 
- 
                                                        Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-Jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides Difficile Infection in the USAAdvances in Therapy, 2023 
 2023Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, Bochan M 
- 
                                                        Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The Optimize I StudyAdvances in Therapy, 2023 
 2023Agiro A, Amin AN, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV 
- 
                                                        Real-World Outcomes Associated with Vonoprazan-Based Versus Proton Pump Inhibitor-Based Therapy for Helicobacter Pylori Infection in JapanTherapeutic Advances in Gastroenterology, 2023 
 2023Howden CW, Cook EE, Swallow E, Yang K, Guo H, Pelletier C, Jacob R, Sugano K 
- 
                                                        Impact on Hospitalizations of Long-Term Versus Short-Term Therapy with Sodium Zirconium Cyclosilicate During Routine Outpatient Care of Patients with Hyperkalemia: The Recognize I StudyExpert Review of Pharmacoeconomics and Outcomes Research, 2023 
 2023Pollack CV, Agiro A, Mu F, Cook EE, Wirtz EL, Young JA, Betts KA, Brahmbhatt YG 
- 
                                                        Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 studyJournal of Medical Economics, 2023 
 2023Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D 
- 
                                                        Assessment of women's treatment preferences for vasomotor symptoms due to menopauseExpert Review of Pharmacoeconomics & Outcomes Research, 2023 
 2023Shiozawa A, Thurston RC, Cook E, Yang H, King DD, Kristy RM, Mancuso S 
- 
                                                        Real-world effectiveness of benralizumab: results from the ZEPHYR 1 StudyAnnals of Allergy, Asthma & Immunology, 2022 
 2022Chung Y, Katial R, Mu F, Cook E, Young J, Yang D, Betts K, Carstens D 
- 
                                                        The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United StatesAdvances in Therapy, 2022 
 2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ 
- 
                                                        Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record AnalysisAdvances in Therapy, 2022 
 2022Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ 
- 
                                                        Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control StudyInternational Journal of Endocrinology, 2022 
 2022Gosmanova EO, Ayodele O, Chen K, Cook EE, Mu F, Young JA, Rejnmark L 
- 
                                                        Inpatient Management and Post-Discharge Outcomes of HyperkalemiaHospital Practice, 2021 
 2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K 
- 
                                                        Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and HyperkalemiaAdvances in Therapy, 2021 
 2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ 
- 
                                                        Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review StudyFrontiers in Medicine, 2021 
 2021Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Hongbo Yang H, Moritz ML 
- 
                                                        August 24, 2024
- 
                                                    September 11, 2024
- 
                                                    March 2, 2023
- 
                                                    April 5, 2022
- 
                                                    July 20, 2021
